Hospital trade group 340B Health has asked pharmaceutical giant Boehringer Ingelheim (BI) to withdraw its plan to cut off discounts for drugs that are distributed by contract pharmacies. However, BI does not appear to be backing down and the German-based company is calling on policymakers to make “significant reform” to the program.
As 340B Report broke on July 1, BI will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.
Hospital trade group 340B Health has asked pharmaceutical giant Boehringer Ingelheim (BI) to withdraw its plan to cut off discounts for drugs that are distributed by contract pharmacies. As 340B Report broke on July 1, BI will stop shipping 340B-purchased drugs to hospitals’ contract pharmacies, effective Aug. 1.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
